Sitokiren
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Sitokiren
- Molecular weight
- 444.54
- Structure (SMILES)
- COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21
- sitokiren
- Sitokiren
- SITOKIREN
- sitokiren [INN]
- sitokiren inn
- sitokirene
- Sitokirene
- SITOKIRENE
- sitokireno
- Sitokireno
- SITOKIRENO
- sph 3127
- Sph-3127
- SPH-3127
- sph3127
- Sph3127
- SPH3127
- SPH3127 100mg
- SPH3127 50mg
- SPH3127 tablet
- CAS registry numbers
- 1399849-02-5
- ChEMBL ID
- CHEMBL4110551
- InChIKey
- GRTDDIZIUSADLD-CRAIPNDOSA-N
- PubChem compound IDs
- 117877477
- FDA ingredient codes (UNII)
- C2M78A9V6Z
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- sitokiren
- Type
- Synthetic organic
- Drug name stem
- -kiren
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- renin
- Gene symbol
- REN
- Protein identifier
- P00797
- Median affinity
- 9.4
- Affinity units
- pIC50
- Mechanism
- Renin inhibitor
- Action type
- Inhibitor
- Target
- Renin
- Protein identifier
- P00797
Open Targets mechanisms
- Mechanism
- Renin inhibitor
- Action type
- Inhibitor
- Target
- Renin
- Condition
- Diabetic Nephropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000401
- Subject identifier
- D003928
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Essential Hypertension
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001134
- Subject identifier
- D000075222
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- NCT03128138
- NCT03249753
- NCT03255993
- NCT03756103
- NCT05593562
- NCT05019742
- NCT05770609
- NCT05359068
- NCT05593575
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 110.61
- Calculated partition coefficient (ALogP)
- 1.53
- Calculated partition coefficient (XLogP)
- 0.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 32
- Molecular formula
- C22H32N6O4
- Monoisotopic mass
- 444.24850352
- Natural product
- No
- Recorded assays
- 22
- Active assays
- 4
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (10)
- A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis
- Drug-drug Interaction Study of SPH3127
- Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease
- Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
- Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
- Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers
- Study on Human Mass Balance of SPH3127 Tablets
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects
- The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People
In development for (4)
- Diabetic kidney disease Phase 2
- Essential hypertension Phase 3
- Hypertensive disorder Phase 2
- Ulcerative colitis Phase 2
Targets (1)
- REN Renin inhibitor